Arcutis Biotherapeutics

Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company that develops and sells topical and systemic treatments for immune-mediated skin diseases, including plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and vitiligo. Its lead FDA-approved product is ZORYVE (roflumilast), sold in cream and foam formulations. The company is publicly traded on Nasdaq under the ticker ARQT.